Home > Blog > Advanced Therapies & Technology Who This Article Is For This article is intended for international patients and families researching deep brain stimulation in China as an advanced assessment pathway after Parkinson’s symptoms have become difficult to manage. It does not determine whether an individual is suitable for surgery. Access Context: A 2024 comparative study indicated that New Zealand had one of the lowest reported DBS utilisation rates among the high-in

Home > Blog > Advanced Therapies & Technology Navigating CAR-T Cell Therapy Options in China When Standard Therapies Fail Key Takeaways Patients with relapsed or refractory hematological malignancies may explore commercial CAR-T cell therapy options in China through specialized clinical hubs. Clinical centers in Beijing are reported to have a high concentration of dual-target CAR-T research and clinical application experience. Reported estimates for commercial CAR-T therapies

Home > Blog > Advanced Therapies & Technology Key Takeaways: The Boao Lecheng pilot zone has reportedly introduced over 557 overseas-approved innovative medicines and devices, though access depends strictly on hospital review and clinical eligibility. Administrative review for eligible "clinical urgent need" products is often described as taking 3 to 7 working days after institutional submission, subject to institutional scheduling policies and product availability. In el

Home > Blog > Advanced Therapies & Technology Key Takeaways: Patients with refractory Claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma may seek a multidisciplinary review in China to evaluate eligibility for newly approved cellular therapies. Medical visa applications require formalized institutional acceptance letters, structured medical records, and specific high-liquidity financial documentation. Institutional protocols enf

Home > Blog > Advanced Therapies & Technology Key Takeaways International patients should be reviewed against aviation, clinical, and institutional baseline requirements before making travel plans. Accessing advanced therapies requires complete, translated dossiers including DICOM imaging and original pathology reports. A structured medical travel to China safety checklist helps organize documents and identify clinical red flags that may preclude safe travel. Quick Answ

Home > Blog > Advanced Therapies & Technology Key Takeaways AstraZeneca is developing a commercial manufacturing base in Guangzhou, China, focused on next-generation radioconjugate drugs, including Actinium-225 targeted therapies. Actinium-225 is an alpha-emitting isotope that induces irreversible double-strand DNA breaks in tumor cells while protecting adjacent healthy tissues due to its extremely short tissue range of 40 to 85 micrometers. Navigating institutional revie

Home > Blog > Advanced Therapies & Technology Key Takeaways Major licensing agreements between global pharmaceutical companies and Chinese biotech firms typically involve compounds in early-stage discovery or clinical development, not commercially available therapies. For international patients, access to investigational oncology programs in China is not automatic and is heavily restricted by institutional criteria, ethics reviews, and specific biomarker requirements. A r

Home > Blog > Advanced Therapies & Technology Key Takeaways Clinical data presented at ASCO 2026 indicated that the antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), combined with pembrolizumab, reduced the risk of disease progression in a specific, previously untreated cohort of patients with advanced non-small cell lung cancer (NSCLC). Access to advanced ADC protocols in China requires documented biomarker evidence, protocol-specific eligibility review, and

Home > Blog > Advanced Therapies & Technology Key Takeaways China hosts approximately 40% of global oncology clinical trials, with a heavy concentration in cellular therapies, antibody-drug conjugates (ADCs), and bispecific antibodies. Eligibility for these experimental protocols is rigorously dictated by precise molecular profiling, previous lines of therapy, and strict physical performance scores. Biological samples and genomic data generated, stored, retested, or trans

Home > Blog > Advanced Therapies & Technology Key Takeaways The Chinese National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) as a cellular pathway for patients with Claudin18.2 (CLDN18.2) positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed at least two prior systemic therapies. Accessing this specialized pathway requires rigorous biomarker confirmation, including the translation

Home > Blog > Advanced Therapies & Technology What Are the Administrative Pathways for Advanced Radiotherapy in China? Key Takeaways China has approved advanced radiotherapy systems, including proton therapy, carbon-ion therapy, and MRI-guided radiotherapy platforms, but these technologies are concentrated within specialized tertiary cancer centers. International patient access is reviewed by hospital specialist departments and depends on case suitability, documentation compl

Home > Blog > Advanced Therapies & Technology Key Takeaways Official data indicates China approved 48 innovative drugs in 2024 and 289 New Drug Applications (NDAs) in 2025. Recent oncology pathways in China rely heavily on specific molecular targets, meaning institutional acceptance requires pre-existing biomarker evidence. For international patients, accessing biomarker-driven oncology treatments in China requires structural preparation, including translated pathology

Home > Blog > Advanced Therapies & Technology Key Takeaways China's nuclear medicine sector functions as a two-speed market; while foundational imaging is widespread, advanced tracers and theranostic workflows remain concentrated within a select group of elite centers. Selected top Chinese hospitals have publicly visible PSMA, DOTATATE, FAPI, and investigational Lu-177 activity, but these workflows are frequently tied to hospital-made tracers, clinical research, or center-s

Home > Blog > Advanced Therapies & Technology Key Takeaways for International Patients A China NMPA approval signifies that a drug has obtained legal marketing authorization in China, but it does not mean a public hospital can immediately prescribe or dispense it to an arriving international patient. Real-world hospital availability requires the completion of provincial procurement listing, internal hospital formulary review, and clinical department adoption. Accelerated regu

Home > Blog > Advanced Therapies & Technology Key Takeaways China's regulatory landscape now includes targeted biologic approvals for generalized myasthenia gravis (gMG), specifically focusing on FcRn inhibitors, BAFF/APRIL modulation, and CD19-directed pathways. Institutional review and access require precisely matched subtype-defining biomarkers, such as AChR or MuSK antibodies, to align with highly specific regulatory labels. Because national approval does not guarante

Home > Blog > Advanced Therapies & Technology Key Takeaways for Accessing Rare Disease Treatment in China Approval of an orphan drug in China does not automatically guarantee hospital stock or immediate administration for traveling patients. Treatment access is typically gated by a required institutional review, often involving a Multidisciplinary Team (MDT) to verify the exact disease subtype and label-defining evidence. A compiled medical file containing original pathol

Home > Blog > Advanced Therapies & Technology Key Takeaways China's oncology trial landscape focuses heavily on biomarker-driven protocols, including ADCs, bispecific antibodies, and CAR-T therapies. Access requires verified molecular evidence before trial-site shortlisting or outreach begins, rather than broad open enrollment. Administrative barriers include language, residency rules, and complex hospital intake systems, necessitating professional coordination. Offi

Before arranging visas, flights, or hospital appointments, MedBridgeNZ helps international patients organize translated oncology records for a China cancer trial eligibility review and pre-travel feasibility assessment. Home > Blog > Advanced Therapies & Technology Key Takeaways Access to innovative Chinese oncology protocols requires navigating strict institutional inclusion criteria, not just verifying regulatory approval. Institutional feasibility heavily depends on exact

MedBridgeNZ Limited helps international patients prepare translated genetic reports, organize medical records, and navigate specialist review pathways for gene-therapy-related care in China. Home > Blog > Advanced Therapies & Technology Key Takeaways Dual-Track Regulatory Framework: China operates a system encompassing both marketed advanced therapies and formal investigator-initiated trials (IITs) guided by hospital ethics committees. Protocol-Driven Eligibility: Instituti

MedBridgeNZ helps international patients prepare translated endoscopy reports, pathology records, and appointment documentation for early GI cancer ESD review pathways in China. Home > Blog > Advanced Therapies & Technology Key Takeaways Specialized gastroenterology centers may provide advanced review and diagnostic pathways for early gastrointestinal tumor detection. Endoscopic Submucosal Dissection (ESD) offers a minimally invasive surgical intervention for the removal of e